Accurate and fast delivery of key events and news of growing Genexine
Genexine will present at the 38th JP Morgan Healthcare Conference.
- Presentation of the interim result of GX-188E's Phase 2 clinical trial for cervical cancer
Young Chul Sung, chairman of Genexine, at the JP Morgan Healthcare Conference, discloses the interim results of Phase 2 clinical trials for cervical cancer applied with Keytruda and GX-188E which is HPV treatment vaccine, and a major pipeline in the clinical phase. The conference is the world's largest bio-investment conference and will be held in San Francisco, USA from January 13, 2020.
Genexine had invited again in 2020, just as it was invited in 2018.
In addition to the clinical results of cervical cancer treatment vaccine, Genexine will also disclose the clinical status of Hyleukin-7, which is being developed as an immuno-cancer drug, and the height growth results of two years of clinical phase 2 of long-acting growth hormone GX-H9, a pediatric growth hormone deficiency.